Clinical Trial

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-19
notable Enrollment reduced: 700 -> 80 participants 2026-05-19
notable Primary completion moved earlier: 2027-12-31 -> 2027-05-12 2026-05-19
Trial Details
NCT Number NCT07462143
Lead Sponsor RemeGen Co., Ltd.
Conditions Colorectal (Colon or Rectal) Cancer
Enrollment 80 participants
Start Date 2026-05-12
Primary Completion 2027-05-12 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-22